Matching companies load automatically. Browse 24 companies per page; expand filters to narrow the results.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
12 matching companiesShowing 1–12 / 12
Crystal Bio Solutions describes bioanalytical and biomarker services, biologics characterization and CMC analytics, and clinical pharmacology. Its website lists immunoassay, molecular, cell-based, and mass-spectrometry techniques. Scope and quality requirements should be confirmed for the specific study and site.
The Baltimore CPC lists FIH, carbon-14 human ADME, TQT and DDI, offered as standalone or integrated studies.
Provides PBPK, IVIVC and formulation/clinical-design modeling, available standalone or integrated with its clinical studies.
Certara offers model-informed drug-development services and biosimulation software. Its public portfolio includes Phoenix for PK/PD analysis and Simcyp for PBPK modeling, alongside development and regulatory support. Software availability does not establish a model's fitness for a particular decision.
Simulations Plus offers modeling and simulation software and consulting across discovery and development. Its public software portfolio includes GastroPlus, MonolixSuite, and QSP tools. Modeling choices and validation should follow the intended scientific question.
Allucent describes clinical pharmacology strategy, PK/PD, pharmacometrics, modeling, and simulation. Nuventra is part of Allucent and is not counted here as a separate independent provider.
Altasciences describes integrated PK, PD, TK, biostatistics, exposure-response, and model-informed approaches from nonclinical translation through early clinical development. Its page identifies collaboration with Certara for model-informed trial design.
ICON lists population PK, PK/PD, exposure-response modeling, trial simulation, first-in-human dose prediction, and formulation-related IVIVC. These are service disclosures, not independent evidence of success for an individual project.
Links Phase I–IIa services to its Secaucus, New Jersey clinic, listing clinical pharmacology, statistics, data management and medical writing.
Parexel describes clinical pharmacology, population PK, PK/PD, exposure-response, PBPK, dose justification, and noncompartmental analysis. Model assumptions, datasets, and intended regulatory use require project-specific review.
Lists early-phase SAD/MAD, DDI, food-effect, BA/BE and PK/PD studies; this does not establish every capability at every site.
Offers NCA and compartmental PK/PD analysis, supporting BA/BE, food-effect, DDI and dose-escalation studies.
Coverage expands from sourced records; this database does not claim all biopharma companies.
